|
Originally published In Press as doi:10.1074/jbc.M107068200 on January 10, 2002
J. Biol. Chem., Vol. 277, Issue 12, 10704-10711, March 22, 2002
Regulation of the Murine Nfatc1 Gene by NFATc2*
Bin
Zhou §,
Randy Q.
Cron§¶,
Bingruo
Wu ,
Anna
Genin¶,
Zhili
Wang ,
Steve
Liu ,
Paul
Robson , and
H.
Scott
Baldwin **
From the Divisions of Cardiology and
¶ Rheumatology, Department of Pediatrics, and the Nucleic
Acid and Protein Core, Joseph Stokes, Jr. Research Institute,
Children's Hospital of Philadelphia,
Philadelphia, Pennsylvania 19104-4318
Received for publication, July 25, 2001, and in revised form, December 26, 2001
 |
ABSTRACT |
NFAT proteins play a key role in the inducible
expression of cytokine genes in T lymphocytes. NFATc1 and NFATc2 are
the predominant NFAT family members in the peripheral immune system.
NFATc2 is found abundantly in the cytoplasm of resting T cells, whereas Nfatc1 expression is induced during T cell activation. To
investigate Nfatc1 regulation, we characterized the
structure of the murine Nfatc1 gene and its 5'-flanking
region. A 290-bp sequence proximal to the transcription start site is
highly conserved between mouse and human and possesses both basal and
inducible promoter activities. Multiple binding sites for transcription
factors were identified within this region, including a consensus
NFAT-binding site. This promoter segment was cyclosporin A-sensitive,
and mutation of the NFAT site abrogated inducible promoter activity and
inhibited formation of an inducible DNA·protein complex containing
NFATc2 in primary T cells. Overexpression of NFATc2 increased inducible Nfatc1 promoter activity, whereas this inducibility was
attenuated in NFATc2 / splenocytes. This study suggests
that pre-existing NFATc2 contributes to the subsequent induction of
Nfatc1 during T cell activation.
 |
INTRODUCTION |
NFAT1 was
originally described as a putative transcription factor present in the
nuclear extract of activated Jurkat T cells that bound to the human
interleukin-2 (IL-2) promoter (1). Since then, four closely related
proteins of the NFAT family have been cloned and partially
characterized. They include NFATc1 (after the HUGO Genome Nomenclature
Committee, previously named NF-ATc, NFAT2) (2), NFATc2 (NF-ATp, NFAT1)
(3, 4), NFATc3 (NF-ATx, NFAT4) (5-7), and NFATc4 (NFAT3) (5). NFAT
proteins have been demonstrated to preferentially bind to a purine-rich
core motif, (A/T)GGAAAA, in the regulatory regions of various cytokine
genes, whereby they modulate the promoter/enhancer transcriptional
activity in activated T cells (8-10).
The regulation of NFAT transcriptional activity during T cell
activation is controlled at several levels. NFAT proteins exist mainly
in an inactive phosphorylated state in the cytoplasm of resting T
cells. Activation requires a sustained increase in intracellular Ca2+ induced by T cell receptor engagement or the calcium
ionophore ionomycin, which in turn activates the
Ca2+-dependent phosphatase calcineurin (11).
Calcineurin dephosphorylates NFAT proteins and induces their nuclear
translocation (4, 12, 13). The immunosuppressants cyclosporin A (CsA)
and FK506, which block the phosphatase activity of calcineurin (14,
15), inhibit T cell activation by preventing the nuclear translocation
of NFAT (16) and subsequent activation of cytokine gene transcription. The nuclear import of NFAT is also blocked by MEKK1 and casein kinase-1 , which mask the nuclear import signal (17). Export of NFAT
out of the nucleus is also highly regulated. Glycogen synthase
kinase-3, a nuclear kinase, phosphorylates NFATc1 at the same sites
that are dephosphorylated by calcineurin and thus promotes NFATc1
nuclear export (18). Similarly, NFATc3 is exported from the
nucleus after phosphorylation by JNK (19). A critical balance between
the import and export of NFAT in and out of the nucleus is a well
established mechanism of NFAT regulation (20).
Several lines of evidence suggest that increased NFAT transcriptional
activity in T cells is not solely due to the nuclear translocation of
NFAT proteins. For example, the DNA-binding affinity of NFAT proteins
is greatly enhanced by cooperative interaction with AP-1 proteins (9).
AP-1 protein synthesis is induced by the activation of protein kinase C
and Ras following T cell receptor engagement. This can be mimicked
in vitro by treatment with the phorbol ester phorbol
12-myristate 13-acetate (PMA). In addition, the transcriptional
activity of NFAT proteins has recently been demonstrated to depend on
the phosphorylation status of critical amino acid residues in the
transcriptional activation domain (21). Finally, levels of NFAT
expression may contribute to overall NFAT activity. NFATc2 is
constitutively expressed in resting human peripheral blood T cells
(22-24), whereas expression of NFATc1 is greatly induced upon T cell
stimulation (2, 22, 24-26). Moreover, the inducible expression of
NFATc1 in activated T cells is CsA-sensitive (22), indicating that the
calcium-dependent calcineurin pathway may regulate NFATc1
induction. However, the factors that directly regulate NFAT expression
levels are unknown.
To better understand the regulation of NFATc1 expression, the murine
Nfatc1 gene and upstream regulatory regions were cloned. Herein, we provide the genomic organization of the murine
Nfatc1 gene and initial characterization of a 6-kb genomic
fragment located upstream of the transcription start site (TSS). A
CsA-sensitive and inducible minimal promoter region containing a
consensus NFAT motif was identified within this 6-kb element.
Mutagenesis studies indicated that this NFAT site is critical for
optimal inducible promoter activity in primary human T cells. Moreover,
this NFAT site bound the NFATc2 protein present in T cell nuclear
extracts, and increased NFATc2 expression in primary T cells augmented
Nfatc1 minimal promoter activity. In contrast, the
inducible Nfatc1 promoter activity was diminished in T cells
deficient in NFATc2. These data suggest a role for NFATc2 in the
regulation of the Nfatc1 gene during the immune response.
 |
MATERIALS AND METHODS |
Isolation and Characterization of Murine Nfatc1 Genomic DNA
Clones--
A mouse Bacterial Artificial Chromosome (BAC)
library (mouse 129/SvJ, Research Genetics, Huntsville, AL) was screened
by PCR and Southern blotting for Nfatc1 gene-specific clones
according to the manufacturer's recommendation. A single clone was
determined to contain the entire coding region of the murine
Nfatc1 gene by Southern blot analysis. To determine the
genomic organization of murine Nfatc1, the intron/exon
borders and gene flanking regions were sequenced on the purified BAC
clone. A range of sequencing oligonucleotide primers flanking the
putative intron/exon boundaries were initially chosen by the cDNA
sequences of murine Nfatc1 isoforms and (GenBankTM/EBI accession numbers AF087434 and AF049606,
respectively) and subsequently by derived sequences.
Rapid Amplification of cDNA Ends (RACE)--
The 5'-RACE
method was carried out using the Sure-RACE kit (Origene, Rockville,
MD), which contains full-length cDNAs from multiple mouse tissues,
following the manufacturer's instructions. Briefly, the 5'-end of
murine Nfatc1 cDNA was amplified by PCR through two
rounds of 30 cycles each at 94 °C for 20 s, followed by
68 °C for 60 s. The primers used in the PCR included the
5'-adapter primers provided by the manufacturer as the sense primers
and the gene-specific primers GSP1 (first round, positions +55 to +74
relative to the translation start site) and GSP2 (second round, positions +30 to +53) as the antisense primers (see Fig. 1). The resulting amplification products were subcloned into pCRII (Invitrogen, Carlsbad, CA) and sequenced.
5'-Primer Extension Analysis--
To confirm the TSS defined by
5'-RACE, 5'-primer extension analysis was carried out using the avian
myeloblastosis virus reverse transcriptase primer extension system
(Promega, Madison, WI). The primer (positions +14 to +36 bp relative to
the putative 5'-end of murine NFATc1 mRNA; see Fig. 1) was
end-labeled with [ -32P]ATP and incubated with 50 µg
of total RNA from the heart, lung, liver, and spleen of a 3-month-old
BALB/c mouse. The extension reaction was carried out according to the
manufacturer's protocol, and the extended products were resolved on a
7 M urea and 6% acrylamide gel in TBE along with
10-bp DNA size markers.
Plasmids and Reporter Constructions--
The mammalian
expression vectors for NFATc1 and NFATc2 have been described elsewhere
(5, 24). The firefly luciferase reporter vector (pGL2-Basic) and the
Renilla luciferase control vector used for transfection
efficiency (pRL-null) were purchased from Promega. The parent murine
Nfatc1 reporter (p6.2) was constructed by insertion of a
6233-bp NheI-XhoI DNA fragment of murine
Nfatc1 (positions 5861 to +372 relative to the TSS) into
the multiple cloning site of the pGL2-Basic vector. A series of
deletion constructs (pX, where X represents the
insert size in kilobases) were generated by consecutive
deletions of the 5'-end of the 6233-bp NheI-XhoI insert in p6.2 by restriction enzyme digestions and religations of the
vector (see Fig. 1). For example, the p0.7 plasmid was generated by
insertion of a 0.7-kb KpnI-XhoI DNA fragment
(positions 351 to +372) upstream of the luciferase gene into
pGL2-Basic. The 5'-end sequences of all deletion constructs were
confirmed by sequencing. The luciferase reporter genes pIL-2-Luc,
pIL-4-Luc, pCMV-Luc, and pNFAT-Luc, which are driven by the human IL-2
promoter, the human IL-4 promoter, the immediate-early cytomegalovirus
promoter, and a multimerized NFAT-binding site, respectively, have been previously described (24, 27).
PCR Mutagenesis--
The p0.7m plasmid with a mutated
NFAT-binding site was generated by PCR-based mutagenesis as previously
described (28). Briefly, two overlapping PCR products carrying the
mutation were generated using p0.7 as a template and two sets of
primers. The first set of primers was the 5'-forward primer
(TGTATCTTATGGTACTGTAACTG) and the 3'-mutation reverse primer
(AGCTGaagAACACCTCCCCCGGCTCCCG). The mutated NFAT site is
underlined, with its mutated core residues indicated by lowercase
letters. The wild-type sequence of the NFAT-binding site on the
noncoding strand is TGGAAAA. The second set of primers was the
5'-mutation forward primer (GTGTTcttCAGCTTTAAAAAGGCAGAAG) and 3'-reverse primer (CTTTATGTTTTTGGCGTCTTCC). After the first round
of PCR, the two overlapping PCR products were used as the template for
the second round of PCR with the 5'-forward and 3'-reverse primers. The
final PCR product was then digested with
KpnI-XhoI before insertion into the multiple
cloning sites of pGL2-Basic. A clone with the desired mutation and no
other sequence alterations was confirmed by sequence analysis.
Isolation of Primary T Cells--
Wild-type BALB/c mice were
purchased from the Jackson Laboratory (Bar Harbor, ME).
NFATc2 / mice on the BALB/c background were kindly
provided by Dr. Laurie H. Glimcher (Harvard University, Cambridge, MA)
(29). The isolation of human whole mononuclear cells from peripheral
blood of healthy adult donors (30) and of whole mononuclear cells from
spleens of 3-4-month-old mice (31) has been described previously.
Human CD4+ T cells were purified by negative selection
using T-helper Lympho-Kwik antibody plus complement reagents (One
Lambda, Inc., Canoga Park, CA) according to the manufacturer's
protocol. For some experiments, CD4+ T cells were expanded
in vitro as described (24)
Reporter Gene Assays--
The protocols used for transient
transfection of nontransformed human and murine CD4+ T
cells have been described previously (31). In brief, after submitogenic
stimulation overnight with concanavalin A (murine) or
phytohemagglutinin (human), 5 × 106 cells were
electroporated in 250 µl of medium at 250 V with 950 microfarads of
resistance in 0.4-cm gap cuvettes (Bio-Rad). Firefly luciferase
reporter constructs (5-10 µg) were co-transfected with or without 10 µg of expression plasmids. All transfections contained 1 µg of the
pRL-null reporter gene (Renilla luciferase) as a control for
transfection efficiency. Following transient transfection with plasmid
DNA, the T cells were activated with 25 ng/ml PMA (Sigma) and 1.5 µM ionomycin (Calbiochem) for 6 h. For experiments involving CsA, 100 ng/ml CsA (Novartis, East Hanover, NJ) was added to
T cell cultures 30 min prior to polyclonal activation. After 6 h
in culture at 37 °C, cells were lysed and analyzed for luciferase
activity as previously described (32) using the Dual-Luciferase Reporter 1000 assay system (Promega). All samples were run in duplicate, and firefly luciferase values were corrected for
transfection efficiency based on Renilla luciferase readings.
Preparation of Nuclear Proteins and Electrophoretic Mobility
Shift Assays (EMSAs)--
In vitro primed human
CD4+ T cells were either left unstimulated or were treated
with 25 ng/ml PMA and 1.5 µM ionomycin for 2 h
before nuclei were harvested. Nuclear extracts were prepared using a
standard protocol. Briefly, cells were washed twice with ice-cold
phosphate-buffered saline and once with cold hypotonic buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride). The cell pellets were resuspended in hypotonic buffer to three times the volume of the cell
pellets, incubated for 10 min on ice, and homogenized with 10 strokes
in a glass Dounce homogenizer using a type B pestle. Nuclei were
pelleted at 3300 × g for 15 min and resuspended in ice-cold low-salt buffer (20 mM Hepes, pH 7.9, 25%
glycerol, 200 mM KCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride). Nuclear proteins were
then extracted by adding an equal volume of ice-cold high-salt buffer (identical to low-salt buffer except containing 1.2 M KCl)
and incubated on ice for 30 min. Debris was removed by centrifugation at 14,000 rpm for 1 h at 4 °C. The supernatants were dialyzed against 50 volumes of binding buffer (10 mM Tris-HCl, pH
7.5, 100 mM KCl, 10% glycerol, 50 ng/ml poly(dI-dC), 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithiothreitol, and 0.2 mM
phenylmethylsulfonyl fluoride) overnight at 4 °C, aliquoted, and
frozen at 80 °C. The protein concentration was estimated using the
bicinchoninic acid protein assay kit (Pierce). Single-stranded
oligonucleotides were 5'-end-labeled with [ -32P]ATP
using T4 polynucleotide kinase, annealed, and purified. The sequences
of the oligonucleotide probes used are listed in Fig. 4. For each
binding reaction, radiolabeled probe (1 × 104 cpm,
0.1 ng) was incubated with 1 µg of nuclear extract in 10 µl of
binding buffer for 10 min at room temperature. Samples were then
analyzed by electrophoresis on pre-cast 6% polyacrylamide gels in
0.5× TBE (Novex, San Diego, CA). When indicated, the nuclear extracts were preincubated with anti-NFAT antibodies on ice for 20 min
before addition of the radiolabeled probes. The anti-NFATc2 antibody
(MA1-025) was obtained from Affinity Bioreagents (Golden, CO), and the
anti-NFATc1 (7A6) and anti-HMG (I)Y (FL-95) antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Northern and Western Blot Analyses--
Northern and Western
blot analyses were carried out using standard protocols. 10 µg of
total RNAs or cell lysates from each treatment was used for Northern
and Western blot analyses, respectively. The probe for Northern blot
analysis was generated by random priming full-length cDNA of
Nfatc1 in the presence of [ -32P]dCTP. The
antibody for Western blot analysis of NFATc1 was 7A6, a mouse
monoclonal antibody, which was used at 1:1000 dilution, followed by
horseradish peroxidase-conjugated rabbit anti-mouse IgG used at 1:5000 dilution.
 |
RESULTS |
Determination of Murine Nfatc1 Genomic Structure and
Transcription Start Site--
To study the transcriptional regulation
of NFATc1, we isolated the murine Nfatc1 gene
from a mouse BAC library. The murine Nfatc1 gene contains
nine exons (Fig. 1A). The
first two exons encode the unique N termini of isoforms and ,
respectively, and translation of isoform or starts from two
alternative ATG start sites (33, 34). It has been postulated that the human NFATc1 gene contains 11 exons (10), and the inducible isoform A is transcribed from the first exon and stops at the proximal
poly(A) site located at exon 9, whereas the two constitutively expressed isoforms B and C are transcribed from the second exon and end
at the distal poly(A) site located at exon 11 (35, 36). However, we
were unable to locate the mouse orthologs of human exons 10 and 11 by
PCR using various degenerate oligonucleotide primers based on the human
NFATc1 cDNA sequence. Moreover, by Northern analysis,
only two murine NFATc1 messages of similar sizes (~4.5 kb) have been
detected in murine splenocytes by us (see Fig. 5) and in murine T cells
by others (33, 34).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 1.
Murine Nfatc1 genomic
organization and TSS. A, the genomic organization of
the murine Nfatc1 gene. The translation start sites for
isoforms and are indicated by bent arrows on top of
exons 1 (E1) and 2 (E2), respectively. The
arrow indicates the 5'-regulatory region. The lengths of
exons are noted. B, sequences of 5'-RACE products. The
locations of primers for 5'-RACE (GSP1 and GSP2) as well as for primer
extension are underlined. The 5'-end of RACE products is
indicated by the black dot, and the asterisk
indicates the terminal nucleotide from the primer extension. The
translation start site for exon 1 is uppercase.
C, 5'-primer extension analysis. Total RNAs (50 µg) from
the hearts (H), lungs (Lu), livers
(Li), and spleens (S) of 3-month-old mice were
used for the 5'-primer extension. The 5'-RACE and primer extension
experiments indicated that the murine NFATc1 TSS is
within the underlined sequence, CACGCGCGCAC.
|
|
We next determined the TSS for exon 1 by RACE using a commercial mouse
panel that contains full-length cDNA from multiple tissues. A
single PCR product was observed in PCR amplification using cDNAs
from the heart, liver, and lung as templates (data not shown).
Sequencing of two RACE products from two separate PCR amplifications
using liver cDNA at two different concentrations (1× and 5×)
indicated that they both started at the same nucleotide, a C (indicated
by the black dot in Fig. 1B), located 160 bases upstream of the translation start site (uppercase). Primer
extension analysis with total RNA extracted from 3-month-mouse heart,
lung, liver, and spleen (Fig. 1C) was then performed to
confirm the 5'-RACE result. A major band of the same size was observed
in all reactions, which stopped at the C nucleotide (indicated by the
asterisk) that is 10 bases upstream of the tentative TSS
defined by 5'-RACE. Thus, the GC-rich motif located 170 to 160 bp
upstream of the translation start site (underlined in Fig.
1B) appears to be a major transcription initiation site for
the murine Nfatc1 gene. The inconsistent results between the
5'-RACE and primer extension analysis and the observation that no
TATA-box like motif is present near the TSS suggest that this 10-bp GC
motif may represent a weak binding site for a transcription initiation
complex. For convenience, we refer to the C nucleotide at the 5'-end of
the GC island as the TSS (position +1).
Identification of an Inducible Nfatc1 Minimal Promoter--
To
determine the sequences essential for efficient transcription of murine
Nfatc1 in T cells, a DNA segment extending from 5861 to
+372 was inserted 5' to a luciferase gene in a reporter construct. The
construct was designated p6.2 according to its insert size in kb. The
6.2-kb inserted DNA contained the putative promoter region, 199 bp of
exon 1, and 173 bp of the 5'-end of the first intron. The promoter
activity of p6.2 was initially tested by transient transfection assays
in primary cultures of mouse splenocytes and thymocytes as well as in
human peripheral whole mononuclear cells in the presence or absence of
PMA plus ionomycin for 6 h. In all three cells, the 6.2-kb
fragment yielded a weak promoter activity (2-fold that of the control
promoterless vector) in the absence of stimulation and a 2-fold
induction in promoter activity after stimulation with PMA and ionomycin
(data not shown). No changes were observed when the cells were
transfected with the control vector after stimulation. These results
suggest that the 6.2-kb DNA fragment acts as a weak promoter in T
cells. Alternatively, a repressor may exist within the 6.2-kb segment.
To further dissect this regulatory region, a series of 5'-end deletions
of p6.2 were generated (Fig.
2A). The resultant constructs are referred to as pX, where X represents the
insert size in kb. Purified human CD4+ T cells were
analyzed for the remainder of the transcriptional assays. The deletion
analysis revealed that a region from 351 to +372 (p0.7) was
sufficient to confer optimal basal as well as inducible promoter
activity in primary CD4+ T cells. Similar results were
obtained using a reporter gene construct containing a region from 351
to +14 that lacks the ATG translation site (data not shown). Further
5'-truncation (p0.4) resulted in a loss of both activities. Thus, this
DNA fragment ( 351 to 61) in p0.7 was defined as the minimal murine
Nfatc1 promoter. Further comparison between p6.2 and p0.7 in
three separate experiments in primary CD4+ cells showed
that p0.7 had an average of 4-fold inducible promoter activity compared
with p6.2 (Fig. 2B), indicating that p0.7 indeed serves as a
minimal promoter. In addition, a drop in transcriptional activity in T
cells transfected with p6.2 compared with p3.6 suggests that a
repressor element may exist between 5861 and 3268. Similarly, a
potential repressor element may be located between 1723 and 352.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2.
Defining the murine Nfatc1
proximal promoter. A, constructs
consisting of various lengths of serial deletions of the murine
Nfatc1 5'-flanking region (lines) were inserted
upstream of the firefly luciferase gene (Luc;
boxes) in the reporter plasmid pGL2-Basic.
Numbers above the constructs indicate nucleotide positions
relative to the TSS (position +1). The firefly luciferase activity of
each construct is presented relative to that of the control plasmid
(p0.4) after normalization to Renilla luciferase activity.
White bars represent unstimulated freshly
isolated human peripheral blood whole mononuclear cells, and
black bars indicate treatment of the cells with PMA (at a
final concentration of 25 ng/ml) and ionomycin (1.5 µM)
(PI) for 6 h. B, shown is the
Nfatc1 promoter activity in primary CD4+ T
cells. Human peripheral blood CD4+ T cells were isolated
and transiently transfected with Nfatc1 promoter reporter
constructs. -Fold induction of the p6.2 and p0.7 plasmids relative to
the control plasmid (p0.4) is displayed along the y axis.
The data are presented as means ± S.D. for three
independent experiments. C, shown is a sequence comparison
between the murine Nfatc1 (GenBankTM accession no. AF480838)
and human NFATc1 proximal promoters. Putative DNA-binding
sites are underlined. Notably, a consensus
NFAT-binding site is located between combinatory sites for
Sp1/Egr and HMG. ATF, activating transcription factor;
CREB, cAMP response element-binding protein.
|
|
Alignment of mouse and human sequences revealed that 297 to +1 of the
minimal promoter region is highly conserved (85% identity at the
nucleotide level) between the two species (Fig. 2C),
suggesting that this region serves as a key regulatory element
conserved in mouse and human. Moreover, several potential binding sites for various T cell transcription factors are located within the region
as determined by screening using the TRANSFAC transcription factor-binding site data base (37). Notably, a consensus NFAT-binding site (TGGAAAA on the noncoding strand) is located at 177 to 171 bp
upstream of the TSS. Flanking the NFAT-binding site immediately 5' is a
G-rich combinatory binding site for Sp1/Egr transcription factors (38,
39). Just 3' of the NFAT site is a short AT-rich region reminiscent of
an HMG I(Y) protein-binding site (40).
The NFAT-binding Site Is Critical for Optimal Transcriptional
Activity of the Murine Nfatc1 Minimal Promoter--
It has previously
been shown that NFATc1 is notably up-regulated at ~6 h after T cell
activation (22, 33, 36). To study this, the p0.7 construct was
transiently transfected into primary human CD4+ T cells.
Cells were then stimulated with PMA plus ionomycin and analyzed for
minimal promoter activity at sequential time points. A steady linear
increase in luciferase activity was observed between 3 and 9 h of
treatment (Fig. 3A). This time
course of promoter activation by PMA/ionomycin mimics the expression of
endogenous NFATc1 protein induced by PMA/ionomycin (22) or
12-O-tetradecanoylphorbol-13-acetate/ionomycin (36) in
normal human peripheral T cells. Moreover, similar to the induction of
NFATc1 protein synthesis in activated T cells (22), this inducible
promoter activity was also completely CsA-sensitive, as documented by
the loss of induction of reporter activity in the presence of CsA (Fig.
3B). This suggested that the potential NFAT-binding site in
the minimal promoter might be involved in regulating NFATc1
transcription. To test this directly, a NFATc2 or NFATc1 expression
vector was co-transfected along with the p0.7 reporter construct.
Exogenous expression of NFATc2 (and to some degree NFATc1 as well)
further augmented the induction of Nfatc1 promoter activity
by PMA plus ionomycin stimulation in T cells (Fig. 3C).
Thus, the NFAT protein was able to up-regulate the inducible murine
Nfatc1 minimal promoter, and the NFAT-binding site within
the minimal promoter was likely involved in this activity. It is
unclear why there appears to be differential activation by NFATc2 and
NFATc1, but this may relate to differences in interactions with
neighboring transcription factors, differential modification of the
transactivation domains, or differences in intrinsic binding affinities
for unique AG-rich regions.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Importance of NFAT to Nfatc1
proximal promoter transcription in primary human CD4+
T cells. A, shown is the time course of induction of
the murine Nfatc1 minimal promoter upon stimulation with PMA
and ionomycin. B, transfected CD4+ T cells were
left untreated (control (c)), treated with PMA plus
ionomycin (PI), or pretreated with CsA before addition of
PMA plus ionomycin (PI+CsA). Luciferase (Luc)
activity is presented relative to the activity of the control plasmid
(p0.4) under identical conditions and normalized to Renilla
luciferase activity. C, the p0.7 reporter was cotransfected
with expression vectors pREP4 (as a control), pREP4/NFATc2, and
pREP4/NFATc1 following PMA plus ionomycin treatment for 6 h.
Luciferase activity is presented relative to the activity of p0.7
cotransfected with the empty parent plasmid (pREP4). The data are
presented as means ± S.E. for three independent experiments.
D, mutation of the core NFAT-binding site in p0.7 (p0.7m)
reduced the basal activity of the Nfatc1 minimal promoter
and abrogated its inducible activity. Luciferase activity is presented
relative to the activity of p0.7 without any treatment (control
(c)). Data are representative of two independent
experiments.
|
|
To confirm the role of the NFAT site, a mutation was introduced into
the NFAT-binding site in p0.7 by a PCR-based strategy to generate
p0.7m. The core (boldface) of the NFAT site in p0.7 (TGGAAAA) was altered in p0.7m
(TGAAGAA, with changes underlined)
to maintain the same A/G ratio, but to disrupt the critical GGA core
sequence required for DNA binding (41). As predicted, mutation of the
NFAT site had a deleterious effect on the inducible activity of the
murine Nfatc1 minimal promoter (Fig. 3D). Little
if any induction of luciferase activity by PMA/ionomycin was observed
in cells transfected with p0.7m. Surprisingly, despite the observation
that mutation of the NFAT site also reduced the basal promoter activity
to 40% of the wild-type promoter activity (Fig. 3D), the
basal promoter activity was not CsA-sensitive (data not shown). Taken
together, we conclude that the NFAT-binding site within the murine
Nfatc1 minimal promoter is required for maintaining its
basal and inducible activities, but that a transcription factor(s)
other than NFAT also participates in the basal activity.
NFATc2 Binds to the NFAT Site within the Murine Nfatc1 Minimal
Promoter--
To determine whether NFAT proteins interact with the
NFAT-binding site within murine Nfatc1 minimal promoter, we
performed the EMSA with three different sets of probes containing
various combinations of putative transcription factor-binding sites
flanking the NFAT site (Fig.
4A). Previously, NFAT proteins
have been shown to bind coordinately with AP-1 (4) or other
transcription factors or coactivators, including c-Maf (42), NIP-45
(43), CBP/p300 (44), GATA-4 (45), Sp1 (46), Ets (47), nuclear
factor- B (48), octamer (49), and HMG I(Y) (50), to the promoter
regions of numerous cytokine genes (8-10). Therefore, to evaluate NFAT binding in the context of neighboring transcription factors, we generated the oligonucleotide probe (SNH) identical to the sequence found in the murine Nfatc1 minimal promoter, consisting of a
5'-combinatory site for Sp1/Egr, the central NFAT-binding site, and a
3'-site for the HMG (I) protein. Two shorter probes were also made by removing the Sp1/Egr or HMG site and termed NH and SN,
respectively.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
NFATc2 binds the Nfatc1
proximal promoter. A, shown are the sequences of
the oligonucleotides used for EMSA. The NFAT site is boxed,
with the NFAT core site in boldface and flanking putative
DNA-binding sites indicated. B, nuclear extracts from primed
human CD4+ T cells untreated or treated with PMA and
ionomycin (PI) for 2 h were reacted with the
double-stranded oligonucleotides listed in A. The slow
migrating complex a is designated, as is the fast migrating complex b.
The inducible complex i is also designated. The complexes supershifted
by anti-NFATc2 and anti-NFATc1 antibodies (Ab) are indicated
by arrows, with associated reductions in complexes a and i.
Free residue probe is noted at the bottom of the gel.
|
|
Nuclear protein extracts from primary human CD4+ T cells
(Fig. 4B) were used for EMSAs. An inducible binding complex
"i" was seen after PMA/ionomycin stimulation. This inducible
complex was supershifted and/or disrupted by antibodies against either
NFATc2 or NFATc1. Moreover, formation of this inducible binding
complex was absent when the NFAT site was mutated (data not shown).
Thus, this NFAT site harbors both NFATc2 and NFATc1 in activated T
cells. Because the inducible NFAT complex was detected in
CD4+ T cells with all three probes, neither the Sp1 nor HMG
site appears to be independently critical for NFAT binding in
CD4+ cells.
Several other binding complexes were also observed in EMSAs, and their
identities remain to be determined. Of these, the fast migrating
complex "b" resembles the HMG I(Y) protein in that it was reduced
by PMA plus ionomycin stimulation and was dependent on the presence of
the 3'-HMG site for binding (50). Despite this, the EMSA carried out
with an antibody specific to HMG I(Y) was unable to identify complex b
(data not shown). The slow migrating complex "a" was constitutively
present in nuclear extracts of primary human CD4+ T cells,
but it was not inducible upon activation when analyzed with the
complete SNH probe. By supershift analysis with NFAT-specific antibodies, it appeared that complex a contained NFATc2 and NFATc1 because anti-NFAT antibodies partially blocked its formation. Because
the consensus NFAT sequence is the binding site for both NFATc1 and
NFATc2, and neither NFATc1 nor NFATc2 is known to form a dimer or
heterodimer, it is likely that NFATc1 and NFATc2 in complex a bound
independently to DNA with other partners. Further experiments will be
required to determine the complete nature of this interaction.
Attenuation of Inducibility of the Murine Nfatc1
Minimal Promoter in NFATc2 / T Cells--
To further
determine whether NFATc2 plays an essential role in the induction of
Nfatc1 promoter activity, the p0.7 construct was transfected
into NFATc2 / splenocytes following overnight
stimulation with concanavalin A. This pre-stimulus allows for T
cell-specific transfection of plasmid DNA (31). The NFAT-responsive
IL-2 and IL-4 minimal promoter reporter constructs (pIL-2-Luc and
pIL-4-Luc, respectively) and an NFAT-dependent reporter in
which multiple NFAT sites have been inserted upstream of luciferase
(pNFAT-Luc) were studied in parallel. Compared with normal splenic T
cells, a decrease in basal promoter activity was observed in
NFATc2 / T cells transfected with the pIL-2-Luc,
pIL-4-Luc, and pNFAT-Luc reporter constructs, whereas p0.7 reporter
activity was modestly increased (Fig.
5A, white bars).
Similarly, both Northern (Fig. 5C) and Western (Fig.
5D) blot analyses showed that the basal level of NFATc1 in
NFATc2 / T cells (lanes 3) was increased
compared with that in normal T cells (lanes 1). The three
protein bands between molecular masses of 79 and 122 kDa on the Western
blot (Fig. 5D) represent the NFATc1 protein recognized by
anti-NFATc1 antibody 7A6. As described previously (22), the predominant
band (~90 kDa, indicated by the arrow) is the inducible
form of NFATc1, whereas the other two bands represent the uninducible
form and/or phosphorylated NFATc1. Upon ionomycin and PMA stimulation,
a reduction in activities of all four reporters, including p0.7, was
found in NFATc2-deficient splenic T cells (Fig. 5A,
black bars). The inducibility of all four reporter genes was
attenuated in NFATc2 / splenic T cells (Fig.
5B, hatched bars) compared with that in normal
cells (shaded bars). By contrast, a comparable increase in
the induction of NFATc1 expression was found in both normal (Fig. 5,
C and D, lanes 2) and
NFATc2 / (lanes 4) splenocytes after 6 h
of polyclonal stimulation in vitro. These data argue that
although NFATc2 is required for optimal induction of Nfatc1
minimal promoter activity in T cells, in vivo it is
dispensable for the overall transcriptional activity of NFATc1.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
Inducible Nfatc1 minimal
promoter activity is attenuated in
NFATc2 / T
cells. Splenic T cells from wild-type or NFATc2 /
mice were transiently transfected with the pIL-2-Luc, pIL-4-Luc, p0.7,
and pNFAT-Luc reporters (representative of the IL-2, IL-4, and murine
Nfatc1 promoters and NFAT-dependent
transcriptional responses, respectively). A, reporter
activity in NFATc2 / cells compared with that in
wild-type cells without (white bars) or with (black
bars) PMA plus ionomycin (PI) stimulation for 6 h.
B, -fold inducible promoter activity in wild-type
(shaded bars) and NFATc2 / (hatched
bars) cells after ionomycin and PMA stimulation. Luciferase
(Luc) activity was normalized between plasmids using
Renilla luciferase activity and to the activity in the
absence of stimulation between mouse cell types using the activity of
the pCMV-Luc reporter construct as a measure of transfection efficiency
as previously described (24). The data are representative of two
independent experiments. C and D, Northern and
Western blot analyses, respectively, of NFATc1 expression in normal
(lanes 1 and 2) and NFATc2 /
(lanes 3 and 4) splenocytes that were
unstimulated (lanes 1 and 3) or were activated by
ionomycin plus PMA (lanes 2 and 4). The
arrows indicate the inducible expression of NFATc1 mRNA
(C) or protein (D). The ethidium bromide staining
of 28 S and 18 S ribosomal RNAs was used as a loading control for the
Northern blot analysis. The Coomassie Blue staining of protein after
transfer was the loading control for Western blot analysis. The blots
represent two independent experiments.
|
|
 |
DISCUSSION |
The NFAT family members are critically important for immune
regulation by effector CD4+ T cells, as most if not all
cytokines produced by these cells are influenced by NFAT activity
(8-10). The importance of the individual NFAT family members has been
demonstrated by the immune phenotypes present in NFAT-deficient mice
(29, 51-60). NFATc1 / T cells display an increased
propensity for the generation of Th1 cytokines, arguing that NFATc1 may
normally play a role in up-regulating the opposing Th2 cytokine
response (55, 56). By contrast, NFATc2 / mice
overexpress Th2 cytokines upon repeated antigenic stimulation and
develop allergic/asthmatic phenotypes (29, 51-54). The regulation of
cytokine immune responses and the subsequent immune responses are thus
notably influenced by the interplay of individual NFAT family members.
Therefore, understanding the regulation of this family of T cell
transcription factors is of utmost importance.
NFATc1 expression in peripheral T cells is predominantly regulated by T
cell activation through T cell receptor engagement, which can be
mimicked in vitro via stimulation with ionomycin and PMA.
Following T cell activation, the level of NFATc1 mRNA is detectable
within 1 h after activation (6) and peaks around 3-6 h (33, 36),
resembling the induction of many T cell-derived cytokine genes.
Furthermore, CsA, a powerful cytokine inhibitor, eliminates inducible
Nfatc1 gene expression (22). The similarity in the
regulation of gene expression between Nfatc1 and cytokine genes supports the contention that NFAT contributes to
Nfatc1 expression.
Here, we provide evidence that the transcriptional activity of
Nfatc1 in T cells is indeed regulated by NFATc2, the most
abundantly expressed NFAT family member in human peripheral T cells
(22, 24, 31). First, the minimal promoter of murine Nfatc1
was defined in primary T cells that were activated by ionomycin plus PMA stimulation. This induction was completely blocked by CsA. Second,
a proximal consensus NFAT-binding motif located within the murine
Nfatc1 minimal promoter was identified, and the sequence of
the NFAT site and surrounding sequences were highly conserved between
mouse and human. Mutational analysis of the NFAT-binding site
demonstrated that this DNA element contributed to optimal basal and
inducible activities of the minimal promoter. Third, the NFAT site was
required for binding of NFATc2 upon T cell activation, and this binding
correlated with increased promoter activity. Last, the inducible
Nfatc1 promoter activity was increased by overexpression of
NFAT, particularly NFATc2. Conversely, this induction was notably
diminished in NFATc2 / T cells. Together, these studies
demonstrate the importance of NFATc2 in increasing NFATc1 expression.
The requirement of the NFAT-binding site for NFATc2 interaction and the
minimal promoter activity of Nfatc1 does not, however, establish that NFATc2 is essential for constitutive or even inducible Nfatc1 expression in vivo. In fact, no alteration
in the level of endogenous NFATc1 protein in DNA·NFAT complexes was
shown by EMSA using nuclear protein extracts from
NFATc2 / mouse splenocytes (54). Furthermore,
constitutive expression of NFATc1 has been reported in mice doubly
deficient in NFATc2 and NFATc3 (58). Similarly, we found, by Northern
and Western blot analyses, an increase in the basal level of NFATc1 in
NFATc2 / splenocytes (Fig. 5, C and
D). In addition, the induction of NFATc1 expression in
NFATc2 / splenocytes after 6 h of polyclonal
stimulation was comparable to that in normal splenocytes. Thus,
dysregulation of NFATc1 coexists with alterations in the expression of
multiple cytokine genes present in Nfatc2 gene-disrupted mice.
One possible explanation for the discrepancy of reporter gene assays
and endogenous NFATc1 expression is that although the optimal
Nfatc1 minimal promoter activity is dependent on NFATc2, its
role is compensated by other transcription factors in the context of
the entire gene in the NFATc2 / splenocytes. Along these
lines, the activity of a potent transcription factor (AP-1) was
markedly increased in NFATc2 / splenocytes, especially
upon PMA and ionomycin activation (>5-fold) (data not shown).
Alternatively, the dysregulated Nfatc1 expression in
NFATc2 / splenocytes may be secondary to functional
redundancy or perturbed thymic development in the knockout mice.
Moreover, T cell function is not entirely normal in
NFATc2 / mice, as the T cells express a preactivated
phenotype and are less susceptible to activation-induced apoptosis
(54). It is therefore possible that NFATc2 does contribute to the
expression of endogenous NFATc1 in T cells. To more directly address
this, it may be necessary to examine the role of NFATc2 in
Nfatc1 transcription at the chromatin level (e.g.
chromatin immunoprecipitation assays) or by a dominant-negative
strategy similar to what has been used to document the requirement for
NFAT in IL-2 expression in vivo (61).
In addition to NFAT, other transcription factors must contribute to
Nfatc1 gene regulation. The gel shift assays suggested that
other protein(s) bind adjacent to the NFAT site in the murine Nfatc1 promoter prior to T cell activation because deletion
either 5' or 3' of the NFAT site from the composite elements abolished the fast migrating complex b (Fig. 4B). Although the
formation of binding complex b was characteristic of HMG (I)Y described for the NFAT-containing composite of the murine IL-4 promoter (50), an
anti-HMG (I)Y antibody was unable to confirm the protein identity
within this complex b. Further experiments will be directed at
examining the possible involvement of members of the HMG family other
than HMG (I)Y.
The complexity of transcription complexes forming at the overlapping
motifs was further manifested by the slow migrating complex a in Fig.
4B. The site immediately 5' of the NFAT motif potentially serves as an overlapping binding site for the constitutively expressed transcription factor Sp1 and inducible Egr-1, which has also been found
in the distal NFAT/AP-1-binding site of the human IL-2 gene (38, 39).
This cooperation of NFAT proteins with AP-1 factors at the NFAT/AP-1
element has been the prototype of synergistic induction of cytokine
gene transcription (9). Sp1 or Egr factors have also been shown to
mediate IL-2, CD95 ligand, and CD40 ligand transcription by functioning
as potent coactivators for NFAT proteins (39, 61, 62). Thus, the close
proximity of the Sp1, NFAT, and HMG sites in the Nfatc1
proximal promoter and the complete conservation of sequences here
between mouse and human suggest an intricate balance in the control of
NFATc1 transcription by several transcription factors. Therefore,
identification of NFAT cofactors and further characterization of their
interactions at the NFAT site will elucidate the higher order assembly
of transcription factors operating in a temporal, cell type-specific,
and stimulus-dependent manner required for NFATc1
transcription during the immune response.
The transcriptional regulation of transcription factors themselves is
only just beginning to be explored. Recently, the Oct-1 transcription
factor promoter was found to possess multiple octamer-binding sites
(63). It is similarly interesting that NFAT proteins are able to
positively regulate self-expression. Transcriptional regulation of
transcription factors will most certainly play a role during embryogenesis and organ development. In the thymus, for example, expression of NFAT family members is differentially regulated during
the development of T cells (26, 64). NFATc3 is preferentially expressed
at a high level in immature double-positive CD4+/CD8
thymocytes. Conversely, NFATc2 is dominantly expressed in mature
single-positive CD4+ T cells. NFATc1, however, is present
at low levels in all subsets of T cells, but is strongly induced upon
treatment with phorbol ester and calcium ionophore (26). Finally,
NFATc1 is both temporary and spatially restricted to a subset of
cardiac endothelial cells and is required for cardiac valve formation
(65, 66). Thus, the Nfatc1 minimal promoter characterized
here will be useful to delineate the transcriptional regulatory
mechanism of NFATc1 in the heart that is important in understanding the
genetic pathway controlling normal cardiac valve development and the
subsequent disease process.
 |
ACKNOWLEDGEMENTS |
We thank Drs. D. B. Lewis (Stanford
University, Palo Alto, CA) and T. H. Finkel (Children's Hospital
of Philadelphia, Philadelphia, PA) for critical reading of the
manuscript and Dr. L. H. Glimcher for the gift of
NFATc2 / mice.
 |
FOOTNOTES |
*
This work was supported by Grant P50HL62177 from the
National Institutes of Health (to H. S. B.) and the Elizabeth Glaser Pediatric AIDS Foundation Grant PF-77638 (to R. Q. C.) and by postdoctoral fellowships from the American Heart Association (to B. Z.
and P. R.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors contributed equally to this work.
**
To whom correspondence should be addressed: Children's Hospital of
Philadelphia, 3615 Civic Center Blvd., ARC 702, Philadelphia, PA
19104-4318. Tel.: 215-590-2938; Fax: 215-590-5454; E-mail: sbaldwin@mail.med.upenn.edu.
Published, JBC Papers in Press, January 10, 2002, DOI 10.1074/jbc.M107068200
 |
ABBREVIATIONS |
The abbreviations used are:
NFAT, nuclear factor of activated
T cells;
IL, interleukin;
CsA, cyclosporin A;
MEKK1, mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase-1;
JNK, c-Jun N-terminal kinase;
PMA, phorbol
12-myristate 13-acetate;
TSS, transcription start site;
RACE, rapid
amplification of cDNA ends;
EMSA, electrophoretic mobility shift
assay;
HMG, high mobility group.
 |
REFERENCES |
| 1.
|
Shaw, J. P.,
Utz, P. J.,
Durand, D. B.,
Toole, J. J.,
Emmel, E. A.,
and Crabtree, G. R.
(1988)
Science
241,
202-205[Abstract/Free Full Text]
|
| 2.
|
Northrop, J. P., Ho, S. N.,
Chen, L.,
Thomas, D. J.,
Timmerman, L. A.,
Nolan, G. P.,
Admon, A.,
and Crabtree, G. R.
(1994)
Nature
369,
497-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
McCaffrey, P. G.,
Luo, C.,
Kerppola, T. K.,
Jain, J.,
Badalian, T. M., Ho, A. M.,
Burgeon, E.,
Lane, W. S.,
Lambert, J. N.,
Curran, T.,
Verdine, G. L.,
Rao, A.,
and Hogan, P. G.
(1993)
Science
262,
750-754[Abstract/Free Full Text]
|
| 4.
|
Jain, J.,
McCaffrey, P. G.,
Miner, Z.,
Kerppola, T. K.,
Lambert, J. N.,
Verdine, G. L.,
Curran, T.,
and Rao, A.
(1993)
Nature
365,
352-355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Hoey, T.,
Sun, Y. L.,
Williamson, K.,
and Xu, X.
(1995)
Immunity
2,
461-472[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Masuda, E. S.,
Naito, Y.,
Tokumitsu, H.,
Campbell, D.,
Saito, F.,
Hannum, C.,
Arai, K.,
and Arai, N.
(1995)
Mol. Cell. Biol.
15,
2697-2706[Abstract]
|
| 7.
|
Ho, S. N.,
Thomas, D. J.,
Timmerman, L. A., Li, X.,
Francke, U.,
and Crabtree, G. R.
(1995)
J. Biol. Chem.
270,
19898-19907[Abstract/Free Full Text]
|
| 8.
|
Crabtree, G. R.,
and Clipstone, N. A.
(1994)
Annu. Rev. Biochem.
63,
1045-1083[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Rao, A.,
Luo, C.,
and Hogan, P. G.
(1997)
Annu. Rev. Immunol.
15,
707-747[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Serfling, E.,
Berberich-Siebelt, F.,
Chuvpilo, S.,
Jankevics, E.,
Klein-Hessling, S.,
Twardzik, T.,
and Avots, A.
(2000)
Biochim. Biophys. Acta
1498,
1-18[Medline]
[Order article via Infotrieve]
|
| 11.
|
Timmerman, L. A.,
Clipstone, N. A., Ho, S. N.,
Northrop, J. P.,
and Crabtree, G. R.
(1996)
Nature
383,
837-840[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Clipstone, N. A.,
and Crabtree, G. R.
(1992)
Nature
357,
695-697[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Shibasaki, F.,
Price, E. R.,
Milan, D.,
and McKeon, F.
(1996)
Nature
382,
370-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Emmel, E. A.,
Verweij, C. L.,
Durand, D. B.,
Higgins, K. M.,
Lacy, E.,
and Crabtree, G. R.
(1989)
Science
246,
1617-1620[Abstract/Free Full Text]
|
| 15.
|
Mattila, P. S.,
Ullman, K. S.,
Fiering, S.,
Emmel, E. A.,
McCutcheon, M.,
Crabtree, G. R.,
and Herzenberg, L. A.
(1990)
EMBO J.
9,
4425-4433[Medline]
[Order article via Infotrieve]
|
| 16.
|
Flanagan, W. M.,
Corthesy, B.,
Bram, R. J.,
and Crabtree, G. R.
(1991)
Nature
352,
803-807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Zhu, J.,
Shibasaki, F.,
Price, R.,
Guillemot, J. C.,
Yano, T.,
Dotsch, V.,
Wagner, G.,
Ferrara, P.,
and McKeon, F.
(1998)
Cell
93,
851-861[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Beals, C. R.,
Sheridan, C. M.,
Turck, C. W.,
Gardner, P.,
and Crabtree, G. R.
(1997)
Science
275,
1930-1934[Abstract/Free Full Text]
|
| 19.
|
Chow, C. W.,
Rincon, M.,
Cavanagh, J.,
Dickens, M.,
and Davis, R. J.
(1997)
Science
278,
1638-1641[Abstract/Free Full Text]
|
| 20.
|
Grabtree, G. R.
(1999)
Cell
96,
611-614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Garcia-Rodriguez, C.,
and Rao, A.
(2000)
Eur. J. Immunol.
30,
2432-2436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Lyakh, L.,
Ghosh, P.,
and Rice, N. R.
(1997)
Mol. Cell. Biol.
17,
2475-2484[Abstract]
|
| 23.
|
Timmerman, L. A.,
Healy, J. I., Ho, S. N.,
Chen, L.,
Goodnow, C. C.,
and Crabtree, G. R.
(1997)
J. Immunol.
159,
2735-2740[Abstract]
|
| 24.
|
Cron, R. Q.,
Bort, S. J.,
Wang, Y.,
Brunvand, M. W.,
and Lewis, D. B.
(1999)
J. Immunol.
162,
860-870[Abstract/Free Full Text]
|
| 25.
|
Sareneva, T.,
Matikainen, S.,
Vanhatalo, J.,
Melen, K.,
Pelkonen, J.,
and Julkunen, I.
(1998)
Immunology
93,
350-357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Amasaki, Y.,
Masuda, E. S.,
Imamura, R.,
Arai, K.,
and Arai, N.
(1998)
J. Immunol.
160,
2324-2333[Abstract/Free Full Text]
|
| 27.
|
Petrak, D.,
Memon, S. A.,
Birrer, M. J.,
Ashwell, J. D.,
and Zacharchuk, C. M.
(1994)
J. Immunol.
153,
2046-2051[Abstract]
|
| 28.
|
Zhou, B.,
Boudreau, N.,
Coulber, C.,
Hammarback, J.,
and Rabinovitch, M.
(1997)
J. Clin. Invest.
100,
3070-3082[Medline]
[Order article via Infotrieve]
|
| 29.
|
Hodge, M. R.,
Ranger, A. M.,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M. J.,
and Glimcher, L. H.
(1996)
Immunity
4,
397-405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Schubert, L. A.,
King, G.,
Cron, R. Q.,
Lewis, D. B.,
Aruffo, A.,
and Hollenbaugh, D.
(1995)
J. Biol. Chem.
270,
29624-29627[Abstract/Free Full Text]
|
| 31.
|
Cron, R. Q.,
Schubert, L. A.,
Lewis, D. B.,
and Hughes, C. C.
(1997)
J. Immunol. Methods
205,
145-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Cron, R. Q.,
Bartz, S. R.,
Clausell, A.,
Bort, S. J.,
Klebanoff, S. J.,
and Lewis, D. B.
(2000)
Clin. Immunol.
94,
179-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Pan, S.,
Koyano-Nakagawa, N.,
Tsuruta, L.,
Amasaki, Y.,
Yokota, T.,
Mori, S.,
Arai, N.,
and Arai, K.
(1997)
Biochem. Biophys. Res. Commun.
240,
314-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Sherman, M. A.,
Powell, D. R.,
Weiss, D. L.,
and Brown, M. A.
(1999)
J. Immunol.
162,
2820-2828[Abstract/Free Full Text]
|
| 35.
|
Chuvpilo, S.,
Zimmer, M.,
Kerstan, A.,
Glockner, J.,
Avots, A.,
Escher, C.,
Fischer, C.,
Inashkina, I.,
Jankevics, E.,
Berberich-Siebelt, F.,
Schmitt, E.,
and Serfling, E.
(1999)
Immunity
10,
261-269[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Chuvpilo, S.,
Avots, A.,
Berberich-Siebelt, F.,
Glockner, J.,
Fischer, C.,
Kerstan, A.,
Escher, C.,
Inashkina, I.,
Hlubek, F.,
Jankevics, E.,
Brabletz, T.,
and Serfling, E.
(1999)
J. Immunol.
162,
7294-7301[Abstract/Free Full Text]
|
| 37.
|
Wingender, E.,
Chen, X.,
Fricke, E.,
Geffers, R.,
Hehl, R.,
Liebich, I.,
Krull, M.,
Matys, V.,
Michael, H.,
Ohnhauser, R.,
Pruss, M.,
Schacherer, F.,
Thiele, S.,
and Urbach, S.
(2001)
Nucleic Acids Res.
29,
281-283[Abstract/Free Full Text]
|
| 38.
|
Skerka, C.,
Decker, E. L.,
and Zipfel, P. F.
(1995)
J. Biol. Chem.
270,
22500-22506[Abstract/Free Full Text]
|
| 39.
|
Decker, E. L.,
Skerka, C.,
and Zipfel, P. F.
(1998)
J. Biol. Chem.
273,
26923-26930[Abstract/Free Full Text]
|
| 40.
|
Chuvpilo, S.,
Schomberg, C.,
Gerwig, R.,
Heinfling, A.,
Reeves, R.,
Grummt, F.,
and Serfling, E.
(1993)
Nucleic Acids Res.
21,
5694-5704[Abstract/Free Full Text]
|
| 41.
|
Chen, L.,
Glover, J. N.,
Hogan, P. G.,
Rao, A.,
and Harrison, S. C.
(1998)
Nature
392,
42-48[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Ho, I. C.,
Hodge, M. R.,
Rooney, J. W.,
and Glimcher, L. H.
(1996)
Cell
85,
973-983[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Hodge, M. R.,
Chun, H. J.,
Rengarajan, J.,
Alt, A.,
Lieberson, R.,
and Glimcher, L. H.
(1996)
Science
274,
1903-1905[Abstract/Free Full Text]
|
| 44.
|
Garcia-Rodriguez, C.,
and Rao, A.
(1998)
J. Exp. Med.
187,
2031-2036[Abstract/Free Full Text]
|
| 45.
|
Molkentin, J. D., Lu, J. R.,
Antos, C. L.,
Markham, B.,
Richardson, J.,
Robbins, J.,
Grant, S. R.,
and Olson, E. N.
(1998)
Cell
93,
215-228[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Xiao, S.,
Matsui, K.,
Fine, A.,
Zhu, B.,
Marshak-Rothstein, A.,
Widom, R. L.,
and Ju, S. T.
(1999)
Eur. J. Immunol.
29,
3456-3465[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Bassuk, A. G.,
Anandappa, R. T.,
and Leiden, J. M.
(1997)
J. Virol.
71,
3563-3573[Abstract]
|
| 48.
|
Sica, A.,
Dorman, L.,
Viggiano, V.,
Cippitelli, M.,
Ghosh, P.,
Rice, N.,
and Young, H. A.
(1997)
J. Biol. Chem.
272,
30412-30420[Abstract/Free Full Text]
|
| 49.
|
Bert, A. G.,
Burrows, J.,
Hawwari, A.,
Vadas, M. A.,
and Cockerill, P. N.
(2000)
J. Immunol.
165,
5646-5655[Abstract/Free Full Text]
|
| 50.
|
Klein-Hessling, S.,
Schneider, G.,
Heinfling, A.,
Chuvpilo, S.,
and Serfling, E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15311-15316[Abstract/Free Full Text]
|
| 51.
|
Xanthoudakis, S.,
Viola, J. P.,
Shaw, K. T.,
Luo, C.,
Wallace, J. D.,
Bozza, P. T.,
Luk, D. C.,
Curran, T.,
and Rao, A.
(1996)
Science
272,
892-895[Abstract]
|
| 52.
|
Kiani, A.,
Viola, J. P.,
Lichtman, A. H.,
and Rao, A.
(1997)
Immunity
7,
849-860[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Heyer, J.,
Kneitz, B.,
Schuh, K.,
Jankevics, E.,
Siebelt, F.,
Schimpl, A.,
and Serfling, E.
(1997)
Immunobiology
198,
162-169[Medline]
[Order article via Infotrieve]
|
| 54.
|
Schuh, K.,
Kneitz, B.,
Heyer, J.,
Bommhardt, U.,
Jankevics, E.,
Berberich-Siebelt, F.,
Pfeffer, K.,
Muller-Hermelink, H. K.,
Schimpl, A.,
and Serfling, E.
(1998)
Eur. J. Immunol.
28,
2456-2466[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Yoshida, H.,
Nishina, H.,
Takimoto, H.,
Marengere, L. E.,
Wakeham, A. C.,
Bouchard, D.,
Kong, Y. Y.,
Ohteki, T.,
Shahinian, A.,
Bachmann, M.,
Ohashi, P. S.,
Penninger, J. M.,
Crabtree, G. R.,
and Mak, T. W.
(1998)
Immunity
8,
115-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Ranger, A. M.,
Hodge, M. R.,
Gravallese, E. M.,
Oukka, M.,
Davidson, L.,
Alt, F. W.,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M.,
and Glimcher, L. H.
(1998)
Immunity
8,
125-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Oukka, M., Ho, I. C,
de la Brousse, F. C.,
Hoey, T.,
Grusby, M. J.,
and Glimcher, L. H.
(1998)
Immunity
9,
295-304[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Ranger, A. M.,
Oukka, M.,
Rengarajan, J.,
and Glimcher, L. H.
(1998)
Immunity
9,
627-635[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Rengarajan, J.,
Mittelstadt, P. R.,
Mages, H. W.,
Gerth, A. J.,
Kroczek, R. A.,
Ashwell, J. D.,
and Glimcher, L. H.
(2000)
Immunity
12,
293-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Peng, S. L.,
Gerth, A. J.,
Ranger, A. M.,
and Glimcher, L. H.
(2001)
Immunity
14,
13-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Dzialo-Hatton, R.,
Milbrandt, J.,
Hockett, R. D., Jr.,
and Weaver, C. T.
(2001)
J. Immunol.
166,
4534-4542[Abstract/Free Full Text]
|
| 62.
|
Lindgren, H.,
Axcrona, K.,
and Leanderson, T.
(2001)
J. Immunol.
166,
4578-4585[Abstract/Free Full Text]
|
| 63.
|
Pankratova, E. V.,
and Polanovsky, O. L.
(1998)
FEBS Lett.
426,
81-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Adachi, S.,
Amasaki, Y.,
Miyatake, S.,
Arai, N.,
and Iwata, M.
(2000)
J. Biol. Chem.
275,
14708-14716[Abstract/Free Full Text]
|
| 65.
|
de la Pompa, J. L,
Timmerman, L. A.,
Takimoto, H.,
Yoshida, H.,
Elia, A. J.,
Samper, E.,
Potter, J.,
Wakeham, A.,
Marengere, L.,
Langille, B. L.,
Crabtree, G. R.,
and Mak, T. W.
(1998)
Nature
392,
182-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Ranger, A. M.,
Grusby, M. J.,
Hodge, M. R.,
Gravallese, E. M.,
de la Brousse, F. C.,
Hoey, T.,
Mickanin, C.,
Baldwin, H. S.,
and Glimcher, L. H.
(1998)
Nature
392,
186-190[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Langworthy, B. Zhou, M. de Caestecker, G. Moeckel, and H. S. Baldwin
NFATc1 Identifies a Population of Proximal Tubule Cell Progenitors
J. Am. Soc. Nephrol.,
February 1, 2009;
20(2):
311 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Fretz, N. K. Shevde, S. Singh, B. G. Darnay, and J. W. Pike
Receptor Activator of Nuclear Factor-{kappa}B Ligand-Induced Nuclear Factor of Activated T Cells (C1) Autoregulates Its Own Expression in Osteoclasts and Mediates the Up-Regulation of Tartrate-Resistant Acid Phosphatase
Mol. Endocrinol.,
March 1, 2008;
22(3):
737 - 750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kim, J. Lee, J. H. Kim, H. M. Jin, B. Zhou, S. Y. Lee, and N. Kim
Protein Inhibitor of Activated STAT 3 Modulates Osteoclastogenesis by Down-Regulation of NFATc1 and Osteoclast-Associated Receptor
J. Immunol.,
May 1, 2007;
178(9):
5588 - 5594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pan, M. M. Winslow, L. Chen, A. Kuo, D. Felsher, and G. R. Crabtree
Enhanced NFATc1 Nuclear Occupancy Causes T Cell Activation Independent of CD28 Costimulation
J. Immunol.,
April 1, 2007;
178(7):
4315 - 4321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. T. C. Yang, P. M. U. Ung, M. Rincon, and C.-W. Chow
Role of the CCAAT/Enhancer-binding Protein NFATc2 Transcription Factor Cascade in the Induction of Secretory Phospholipase A2
J. Biol. Chem.,
April 28, 2006;
281(17):
11541 - 11552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Q. Cron, R. Bandyopadhyay, A. Genin, M. Brunner, G. J. Kersh, J. Yin, T. H. Finkel, and M. K. Crow
Early Growth Response-1 Is Required for CD154 Transcription
J. Immunol.,
January 15, 2006;
176(2):
811 - 818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Y. Wang, S. Kusam, V. Munugalavadla, R. Kapur, R. R. Brutkiewicz, and A. L. Dent
Regulation of Th2 Cytokine Expression in NKT Cells: Unconventional Use of Stat6, GATA-3, and NFAT2
J. Immunol.,
January 15, 2006;
176(2):
880 - 888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Asagiri, K. Sato, T. Usami, S. Ochi, H. Nishina, H. Yoshida, I. Morita, E. F. Wagner, T. W. Mak, E. Serfling, et al.
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis
J. Exp. Med.,
November 7, 2005;
202(9):
1261 - 1269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Zhou, B. Wu, K. L. Tompkins, K. L. Boyer, J. C. Grindley, and H. S. Baldwin
Characterization of Nfatc1 regulation identifies an enhancer required for gene expression that is specific to pro-valve endocardial cells in the developing heart
Development,
March 1, 2005;
132(5):
1137 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. K. Liu, X. Lin, and S. L. Gaffen
Crucial Role for Nuclear Factor of Activated T Cells in T Cell Receptor-mediated Regulation of Human Interleukin-17
J. Biol. Chem.,
December 10, 2004;
279(50):
52762 - 52771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Matsumoto, M. Kogawa, S. Wada, H. Takayanagi, M. Tsujimoto, S. Katayama, K. Hisatake, and Y. Nogi
Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1
J. Biol. Chem.,
October 29, 2004;
279(44):
45969 - 45979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Monticelli, D. C. Solymar, and A. Rao
Role of NFAT Proteins in IL13 Gene Transcription in Mast Cells
J. Biol. Chem.,
August 27, 2004;
279(35):
36210 - 36218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Rosenberg, A. Hawkins, J. Stiber, J. M. Shelton, K. Hutcheson, R. Bassel-Duby, D. M. Shin, Z. Yan, and R. S. Williams
TRPC3 channels confer cellular memory of recent neuromuscular activity
PNAS,
June 22, 2004;
101(25):
9387 - 9392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Matsuo, D. L. Galson, C. Zhao, L. Peng, C. Laplace, K. Z. Q. Wang, M. A. Bachler, H. Amano, H. Aburatani, H. Ishikawa, et al.
Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos
J. Biol. Chem.,
June 18, 2004;
279(25):
26475 - 26480.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Mann, J. L. Ray, E. S. Moon, K. M. Sass, and M. R. Benson
Calcineurin initiates smooth muscle differentiation in neural crest stem cells
J. Cell Biol.,
May 24, 2004;
165(4):
483 - 491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Wu, S.-C. Hsu, H.-m. Shih, and M.-Z. Lai
Nuclear Factor of Activated T Cells c Is a Target of p38 Mitogen-Activated Protein Kinase in T Cells
Mol. Cell. Biol.,
September 15, 2003;
23(18):
6442 - 6454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. G. Hogan, L. Chen, J. Nardone, and A. Rao
Transcriptional regulation by calcium, calcineurin, and NFAT
Genes & Dev.,
September 15, 2003;
17(18):
2205 - 2232.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|